Completed PHASE2 INTERVENTIONAL 1-arm NCT05285787

A Clinical Trial of Epizon-701 (EPN-701) in Subjects With End-Stage Renal Disease (ESRD)

A Phase 2 Prospective Safety/Tolerability, Pharmacokinetics, Surrogate Biomarkers as Proxies for Efficacy Trial of EPN-701 in Subjects With Stable End Stage Renal Disease (ESRD) Receiving Outpatient Hemodialysis

Sponsor: Epizon Pharma, Inc.

Conditions End-Stage Renal Disease (ESRD)

Interventions EPN-701 (Oral)

Updated 4 times since 2022 Last updated: Sep 3, 2024 Started: Mar 1, 2019 Primary completion: Apr 30, 2021 Completion: Apr 30, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates End-Stage Renal Disease (ESRD) and is currently completed. Epizon Pharma, Inc. leads this study, which shows 4 recorded versions since 2019 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

4 versions recorded

Oct 2024 — Present [monthly]

Completed PHASE2
Sep 2024 — Oct 2024 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Apr 2022 — Jul 2024 [monthly]

Completed PHASE2

First recorded

Mar 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Epizon Pharma, Inc.

Data source: Epizon Pharma, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Augusta, United States